Market Closed -
Swiss Exchange
11:31:30 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.1155
CHF
|
+0.43%
|
|
-23.26%
|
+151.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
43.44
|
53.24
|
39.42
|
10.39
|
6.181
|
14.81
|
-
|
Enterprise Value (EV)
1 |
12.06
|
34.48
|
19.4
|
3.801
|
6.181
|
14.45
|
7.587
|
P/E ratio
|
-2.93
x
|
-4.15
x
|
-2.31
x
|
-0.22
x
|
-0.33
x
|
-1.28
x
|
2.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.7
x
|
13.7
x
|
12.5
x
|
7.19
x
|
3.75
x
|
-
|
1.38
x
|
EV / Revenue
|
4.37
x
|
8.89
x
|
6.15
x
|
2.63
x
|
3.75
x
|
-
|
0.71
x
|
EV / EBITDA
|
-0.85
x
|
-2.91
x
|
-1.28
x
|
-0.19
x
|
-
|
-1.96
x
|
30.3
x
|
EV / FCF
|
-1.27
x
|
-2.82
x
|
-1.32
x
|
-0.23
x
|
-
|
-2.29
x
|
0.55
x
|
FCF Yield
|
-78.8%
|
-35.5%
|
-76%
|
-432%
|
-
|
-43.6%
|
181%
|
Price to Book
|
1.71
x
|
3.69
x
|
2.33
x
|
1.58
x
|
-
|
3.85
x
|
0.89
x
|
Nbr of stocks (in thousands)
|
26,485
|
26,754
|
37,903
|
103,234
|
134,374
|
128,257
|
-
|
Reference price
2 |
1.640
|
1.990
|
1.040
|
0.1006
|
0.0460
|
0.1155
|
0.1155
|
Announcement Date
|
4/8/20
|
3/11/21
|
3/10/22
|
3/30/23
|
4/18/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2.763
|
3.879
|
3.153
|
1.445
|
1.647
|
-
|
10.75
|
EBITDA
1 |
-14.27
|
-11.86
|
-15.16
|
-20.2
|
-
|
-7.392
|
0.25
|
EBIT
1 |
-14.6
|
-12.24
|
-15.51
|
-20.52
|
-10.28
|
-7.392
|
0.21
|
Operating Margin
|
-528.56%
|
-315.62%
|
-491.79%
|
-1,420.07%
|
-624.23%
|
-
|
1.95%
|
Earnings before Tax (EBT)
1 |
-14.78
|
-12.86
|
-15.35
|
-20.8
|
-10.56
|
-6.3
|
0.05
|
Net income
1 |
-14.78
|
-12.86
|
-15.35
|
-20.8
|
-10.56
|
-6.3
|
0.05
|
Net margin
|
-534.96%
|
-331.5%
|
-486.9%
|
-1,439.72%
|
-640.92%
|
-
|
0.47%
|
EPS
2 |
-0.5600
|
-0.4800
|
-0.4500
|
-0.4600
|
-0.1400
|
-0.0900
|
0.0550
|
Free Cash Flow
1 |
-9.511
|
-12.24
|
-14.74
|
-16.44
|
-
|
-6.3
|
13.7
|
FCF margin
|
-344.21%
|
-315.53%
|
-467.39%
|
-1,137.56%
|
-
|
-
|
127.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
5,480%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
27,400%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/8/20
|
3/11/21
|
3/10/22
|
3/30/23
|
4/18/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.7578
|
0.4009
|
0.244
|
0.186
|
0.4157
|
-
|
0.329
|
0.1534
|
0.7
|
0.7
|
0.7
|
0.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-3.576
|
-4.275
|
-5.763
|
-7.092
|
-4.167
|
-
|
-2.652
|
-2.682
|
-
|
-
|
-
|
-
|
Operating Margin
|
-471.9%
|
-1,066.3%
|
-2,361.89%
|
-3,812.9%
|
-1,002.4%
|
-
|
-806.08%
|
-1,748.07%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-3.598
|
-4.424
|
-5.824
|
-7.221
|
-4.108
|
-
|
-2.617
|
-2.857
|
-
|
-
|
-
|
-
|
Net income
|
-3.598
|
-4.424
|
-5.824
|
-7.221
|
-4.108
|
-2.675
|
-2.617
|
-2.857
|
-
|
-
|
-
|
-
|
Net margin
|
-474.81%
|
-1,103.46%
|
-2,386.89%
|
-3,882.26%
|
-988.12%
|
-
|
-795.44%
|
-1,861.74%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1100
|
-0.1300
|
-0.1500
|
-0.1900
|
-0.0900
|
-0.0400
|
-0.0300
|
-0.0300
|
-0.0200
|
-0.0200
|
-0.0200
|
-0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/10/22
|
5/5/22
|
7/30/22
|
11/11/22
|
8/10/23
|
11/29/23
|
4/18/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
31.4
|
18.8
|
20
|
6.58
|
-
|
0.36
|
7.23
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-9.51
|
-12.2
|
-14.7
|
-16.4
|
-
|
-6.3
|
13.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.9600
|
0.5400
|
0.4500
|
0.0600
|
-
|
0.0300
|
0.1300
|
Cash Flow per Share
|
-0.3600
|
-0.4600
|
-0.4300
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.06
|
0.03
|
0
|
-
|
-
|
-
|
Capex / Sales
|
-
|
1.53%
|
1%
|
0.04%
|
-
|
-
|
-
|
Announcement Date
|
4/8/20
|
3/11/21
|
3/10/22
|
3/30/23
|
4/18/24
|
-
|
-
|
Last Close Price
0.1155
CHF Average target price
0.16
CHF Spread / Average Target +38.53% Consensus |
1st Jan change
|
Capi.
|
---|
| +151.09% | 16.19M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|